摘要
The management of intermediate-stage hepatocellular carcinoma(HCC)continues to evolve,yet transarterial chemoembolization(TACE)remains a cornerstone of therapy for patients with Barcelona Clinic Liver Cancer(BCLC)stage B disease(1,2).Despite its widespread adoption,the optimal choice of chemotherapeutic agent in TACE-especially with drug-eluting bead(DEB)platforms-has long remained controversial(3,4).
